tiprankstipranks
Trending News
More News >

Allogene Therapeutics Holds Annual Stockholder Meeting

Story Highlights
Allogene Therapeutics Holds Annual Stockholder Meeting

Confident Investing Starts Here:

An update from Allogene Therapeutics ( (ALLO) ) is now available.

On June 18, 2025, Allogene Therapeutics held its Annual Meeting of Stockholders, where key decisions were made. Stockholders elected three Class I Directors to serve until 2028, approved executive compensation on an advisory basis, and ratified Ernst & Young LLP as the independent accounting firm for 2025.

The most recent analyst rating on (ALLO) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Allogene Therapeutics stock, see the ALLO Stock Forecast page.

Spark’s Take on ALLO Stock

According to Spark, TipRanks’ AI Analyst, ALLO is a Neutral.

Allogene Therapeutics is facing substantial financial challenges with persistent losses and reliance on external funding, which significantly impacts its stock score. The technical analysis indicates bearish momentum, and valuation metrics show a lack of profitability. Despite some positive developments from the earnings call regarding clinical trials and cash management, these are not enough to offset the broader financial and operational hurdles.

To see Spark’s full report on ALLO stock, click here.

More about Allogene Therapeutics

Allogene Therapeutics, Inc. operates in the biotechnology industry, focusing on the development of allogeneic CAR T cell therapies for cancer treatment.

Average Trading Volume: 3,084,606

Technical Sentiment Signal: Sell

Current Market Cap: $269M

For a thorough assessment of ALLO stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1